Pharmaids Pharmaceuticals Limited (BOM:524572)

Pharmaids Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	1.34	21.45	48.04	127.54	4.07
Short-Term Investments	-	-	-	33.05	-
Cash & Short-Term Investments	1.34	21.45	48.04	160.59	4.07
Cash Growth	-93.77%	-55.36%	-70.09%	3841.48%	103.44%
Accounts Receivable	34.29	31.28	26.79	20.54	13.39
Receivables	34.29	31.28	26.79	20.54	13.39
Inventory	4.11	121.84	35.91	-	8.88
Prepaid Expenses	-	4.02	1.57	-	-
Other Current Assets	70.18	44.48	23.01	2.02	0.34
Total Current Assets	109.91	223.07	135.32	183.16	26.68
Property, Plant & Equipment	286.18	491.8	384.59	21.06	4.81
Goodwill	314.17	314.17	314.17	-	-
Other Intangible Assets	-	5.45	5.45	-	-
Long-Term Accounts Receivable	-	-	-	-	14.16
Long-Term Deferred Tax Assets	122.78	105.03	66.68	27.08	3.56
Long-Term Deferred Charges	-	-	-	1.21	-
Other Long-Term Assets	39.58	59	7.21	0.85	61.92
Total Assets	872.62	1,199	913.41	245.85	111.12

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	27.8	163.21	51.18	18.83	23.06
Accrued Expenses	0.47	6.58	4.62	0.28	-
Short-Term Debt	-	40.57	11.53	-	-
Current Portion of Long-Term Debt	90.69	10.06	6.14	-	-
Current Portion of Leases	6.42	7.93	7.13	-	-
Current Income Taxes Payable	-	0.26	-	-	-
Other Current Liabilities	114.71	58.53	35.16	2.14	1.35
Total Current Liabilities	240.09	287.15	115.76	21.25	24.41
Long-Term Debt	118.44	301.84	35.85	-	-
Long-Term Leases	18.27	29.35	24.68	-	-
Pension & Post-Retirement Benefits	1.79	7.78	6.15	-	-
Other Long-Term Liabilities	18	22	26	-0	-
Total Liabilities	396.6	648.11	208.44	21.25	24.41

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	352.68	352.68	352.68	214.44	102.69
Additional Paid-In Capital	-	505.75	505.75	104.24	-
Retained Earnings	-	-266.77	-139.3	-98.89	-23.33
Comprehensive Income & Other	123.86	1.55	1.34	4.81	7.36
Total Common Equity	476.54	593.2	720.47	224.6	86.72
Minority Interest	-0.51	-42.79	-15.5	-	-
Shareholders' Equity	476.03	550.42	704.97	224.6	86.72
Total Liabilities & Equity	872.62	1,199	913.41	245.85	111.12

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	233.82	389.75	85.33	-	-
Net Cash (Debt)	-232.49	-368.3	-37.29	160.59	4.07
Net Cash Growth	-	-	-	3841.48%	103.44%
Net Cash Per Share	-6.57	-10.44	-1.64	12.45	0.40
Filing Date Shares Outstanding	35.47	35.27	35.27	21.49	10.31
Total Common Shares Outstanding	35.47	35.27	35.27	21.49	10.31
Working Capital	-130.18	-64.07	19.56	161.91	2.27
Book Value Per Share	13.43	16.82	20.43	10.45	8.41
Tangible Book Value	162.37	273.59	400.85	224.6	86.72
Tangible Book Value Per Share	4.58	7.76	11.37	10.45	8.41
Land	-	254.5	178.22	-	-
Buildings	-	7.72	6.08	-	-
Machinery	-	184.48	116.88	-	5.09
Construction In Progress	-	45.3	70.01	-	4.5

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error